Dr. Erwin Grussie
Hematology (Hematology (Internal Medicine) Physician)
11800 Wilshire Blvd # 2f
Los Angeles, CA 90025
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 18
- In the NPI registry since
- 2013
- Medicare patients seen, 2024
- 515
Licensed in California since 2015, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2013Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
CA license A138355 (first issued 2015; current) -
Hematology & Oncology Physician
CA license A138355 (first issued 2015; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Cedars-Sinai Medical Center Los Angeles, CA
- Saint John's Health Center Santa Monica, CA
- Providence Saint Joseph Medical Ctr Burbank, CA
- Cedar-Sinai Marina Del Rey Hospital Marina Del Rey, CA
Medical groups
- Cedars-Sinai Medical Care Foundation (1,692 clinicians)
- Providence Medical Institute (288 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 515
- Services billed
- 22,213
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Injection, denosumab, 1 mg | 7,560 | 18 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 3,860 | 11 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 1,694 | 339 |
| Insertion of needle into vein for collection of blood sample | 1,597 | 328 |
| Blood test, comprehensive group of blood chemicals | 1,512 | 329 |
| Established patient office or other outpatient visit, 30-39 minutes | 1,485 | 270 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 645 | 178 |
| Lactate dehydrogenase (enzyme) level | 548 | 191 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 350 | 141 |
| Injection of drug or substance under skin or into muscle | 293 | 52 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Eliquis (apixaban) Other prescribers in Los Angeles, CA | 99 |
| Anastrozole Other prescribers in Los Angeles, CA | 96 |
| Abiraterone Acetate | 87 |
| Prednisone Other prescribers in Los Angeles, CA | 83 |
| Prochlorperazine Maleate Other prescribers in Los Angeles, CA | 54 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Los Angeles, CA | 51 |
| Alendronate Sodium Other prescribers in Los Angeles, CA | 49 |
| Dexamethasone Other prescribers in Los Angeles, CA | 46 |
| Hydroxyurea Other prescribers in Los Angeles, CA | 45 |
| Kisqali (ribociclib succinate) | 45 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 8 payments worth $467 in total to this clinician.
| Exelixis Inc. | $337 |
|---|---|
| Daiichi Sankyo Inc. | $56.71 |
| Pfizer Inc. | $50.74 |
| Pulmonx Corporation | $22.69 |
| Food and Beverage | $436 |
|---|---|
| Education | $30.65 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Aug 4, 2025 | Education IBRANCE · ONCOLOGY · in-kind | $30.65 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 4 companies. The companies reported $5,880 in research payments for these studies, mostly to the institutions running them.
- Study name not reported
Myriad Genetic Laboratories, Inc. - T DM1 Atezolizumab in high risk HER2 patients with residual disease
Genentech, Inc. - Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
Eli Lilly and Company · Active, not recruiting · NCT03155997 - A randomized phase 3 double-blinded study comparing the efficacy and s
GlaxoSmithKline, LLC.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.